The researchers identified a gene that potentially doubles the risk of death from COVID-19, with the company's technology used to identify the gene. Study authors called the gene LZTFL1 (Nature Genetics, Vol. 53, pp. 1606-1615).

The study's authors suggest that a higher level of LZTFL1 likely prevents the cells lining the airways and the lungs from fighting the virus properly, but it doesn't affect the immune system. The authors added that individuals carrying this version are likely to particularly benefit from vaccination.

Nucleome resolves 3D genome structure at single-base-pair level
Nucleome Therapeutics has gained an exclusive license from its academic founders at the University of Oxford to a micro capture-C method that maps the...